
Hologic, Inc.

HOLX (Hologic, Inc.) trades at 4.2x EV/Revenue — reasonably priced for a healthcare & pharma company with strong gross margins (61%) and mature growth profile (+3% YoY). The business is profitable at 25% EBIT margins. Forward PE of 17x.
Diversification is the only free lunch in investing — but over-diversification can hurt returns. 15-25 stocks captures 95% of the benefit.
Gold Eagle provides data and AI-generated analysis for informational purposes only. Not investment advice. All data from public sources.
Hologic (HOLX) is a medical technology company focused on women's health, developing diagnostic equipment, surgical products, and medical imaging systems. They serve hospitals, clinics, and laboratories with products ranging from mammography machines and bone density scanners to molecular diagnostics tests. The company generates revenue through equipment sales, recurring consumables, and service contracts.
Limited recent financial data makes it difficult to assess current growth trajectory, though the women's health diagnostics market is expected to grow mid-single digits annually. Growth is typically driven by new product launches, international expansion, and increased screening adoption in emerging markets.
Historical data shows Hologic has maintained healthy gross margins (typically 60-70%) due to its specialized product portfolio and consumables business. Operating margins have generally improved over time as the company has scaled and focused on higher-margin segments within women's health.
Hologic holds leadership positions in breast health imaging and molecular diagnostics for women's health applications. The company has built strong relationships with healthcare providers and benefits from switching costs associated with installed equipment base. Key competitors include Siemens Healthineers, GE Healthcare, and Roche Diagnostics.
Without access to recent earnings data, current momentum is unclear. Historically, the company has benefited from steady procedure volume growth and new product introductions, though COVID-19 impacts on routine screening procedures have created volatility in the diagnostic imaging sector.
Analyst sentiment data is not available, but the medical device sector generally faces mixed views as investors weigh healthcare spending growth against pricing pressures and regulatory uncertainties. Women's health remains viewed as a defensive end market with steady long-term demand drivers.
Hologic is a specialized medical device company with leading positions in women's health diagnostics, offering investors exposure to demographic trends and recurring revenue streams, though recent performance data is needed to assess current execution.








| '25E | '26E | '27E | '28E | |
|---|---|---|---|---|
| Revenue | $4.1B | $4.2B | $4.4B | $4.6B |
| Growth | — | +3% | +5% | +4% |
| EBITDA | — | $1.5B | $1.6B | $1.6B |
| Growth | — | +5% | +4% | |
| FCF | $920M | — | — | — |
| Margin | 23% | — |
1.5 Billion Women Miss Essential Preventive Tests, Despite Uptick in Global Screening Rates
Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio
Hologic Announces Financial Results for First Quarter of Fiscal 2026
| — |
| — |
| EPS (PF) | $4.24 | $4.43 | $4.83 | $5.17 |
| Growth | — | +4% | +9% | +7% |